Astrazeneca

FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (139)Eneboparatide normalised serum calcium and achieved independence from supplements in 31.1% of adults with HypoPT in CALYPSO Phase III trial
Preheader (150)Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparath
Typography
Arial
Colors
Text Analysis
Body Words171
Subject Words20
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px840 px
X-Spam Score-0.5
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeOvernight

Eneboparatide normalised serum calcium and achieved independence from supplements in 31.1% of adults with HypoPT in CALYPSO Phase III trial

Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparath
Eneboparatide normalised serum calcium and achieved independence from supplements in 31.1% of adults with HypoPT in CALYPSO Phase III trial